(Date of earliest event reported): August 30,

SECTION 13 OR 15(d) OF

EXCHANGE ACT OF 1934

(Date of earliest event reported): August 30,

Registrant as Specified in its Charter)

Registrant's telephone

number, including area code

(Former name or former

address, if changed since last report)

Check the appropriate box below if

the Form 8-K filing is intended to simultaneously satisfy the

filing obligation of the registrant under any of the following

General Instruction A.2. below):

Written communications pursuant to

Rule 425 under the Securities Act (17 CFR

Soliciting material pursuant to

Rule 14a-12 under the Exchange Act (17 CFR

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

Indicate by check mark whether the registrant is

an emerging growth company as defined in Rule 405 of the Securities

Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 ( 240.12b-2 of this chapter).

emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided

pursuant to Section 13(a) of the Exchange

Securities registered pursuant to

Section 12(b) of the Act:

2019, Edesa Biotech, Inc., formerly known as Stellar

Biotechnologies, Inc. (the Company ), filed a

Current Report on Form 8-K with the Securities and Exchange

Commission reporting, among other items, that on June 7, 2019, the

Company completed its business combination with Edesa Biotech

Research, Inc., formerly known as Edesa Biotech Inc.

This Current Report on Form 8-K is being filed with the Securities

and Exchange Commission to report certain contracts entered into by

Edesa prior to its business combination with the

Item 8.01 Other Items

January 1, 2017, Edesa entered into a lease agreement with 1968160

Ontario Inc. (the Lease Agreement ) pursuant to which

Edesa leased approximately 2,800 square feet of office space

located at 100 Spy Court, Markham, Ontario Canada (the

Premises ). 1968160 Ontario Inc. at the time of

entry into the agreement was an affiliate of Edesa. The Premises now serves as the corporate

headquarters of the Company. The rent per month is $8,320 (Cdn),

with the rent payment increasing by $1 per square foot every two

years. Subject to certain exceptions, the rent includes

Edesa's proportionate share of the costs of maintaining and

repairing common areas and common facilities of the building and

Edesa's utilities, security janitorial services and share of

insurance and property taxes for the building. The lease is

scheduled to terminate on December 31, 2022, subject to Edesa

having a right to renew the lease for an additional period of two

years. Edesa also has the right to terminate the lease at any time

upon one month's notice to the

The foregoing description of the

Lease Agreement contained herein does not purport to be complete

and is qualified in its entirety by reference to the Lease

Agreement, which is attached hereto as Exhibit 10.1 and

incorporated herein by reference.

License Agreement with Yissum

June 29, 2016, Edesa entered into an exclusive license agreement

with Yissum Research

Development Company, the technology transfer company of the Hebrew

University of Jerusalem Ltd. ( Yissum ), which

agreement was subsequently amended on each of April 3, 2017 and May

7, 2017. Pursuant to the license agreement as amended, Edesa

obtained exclusive rights throughout

the world to certain know-how, patents and data relating to a

pharmaceutical product. Edesa will use the exclusive rights to

develop the product for therapeutic, prophylactic and diagnostic

uses in topical dermal applications and anorectal applications (the

Field ). Unless earlier terminated, the term of the

license agreement will expire on a country by country basis on the

later of (i) the date of expiry of the last valid licensed patent

in such country; (ii) the date of expiry of any period of

exclusivity granted to a product by a regulatory authority in such

country or (iii) the date that is fifteen (15) years after the

first commercial sale of a product in such

the license agreement, Edesa is exclusively responsible, at its

expense, for the development of the product in the Field, including

conducting clinical trials and seeking regulatory approval for the

product, and once regulatory approval has been obtained, for the

commercialization of the product. Edesa is required to use its

commercially reasonable efforts to develop and commercialize the

product in the Field in accordance with the terms of a development

plan established by the parties. Subject to certain conditions,

Edesa is permitted to engage third parties to perform its

activities or obligations under the agreement.

for the exclusive rights to develop and commercialize the product

in the Field, Edesa is committed to payments of various amounts to

Yissum upon meeting certain milestones outlined in the license

agreement up to an aggregate amount of $18.6 million. In addition,

upon divestiture of substantially all of the assets of Edesa, Edesa

is obligated to pay Yissum a percentage of the valuation of the